NCT05508568 - A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

650

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

April 30, 2023

Conditions

Bladder Cancer

Interventions

DIAGNOSTIC_TEST

ADXBLADDER

ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.

Trial Locations (13)

13210

RECRUITING

Associated Medical Professionals of NY, Syracuse

19004

RECRUITING

MidLantic Urology, Philadelphia

23235

RECRUITING

Virginia Urology Center, Richmond

23462

RECRUITING

Urology of Virginia, Virginia Beach

29572

RECRUITING

Carolina Urologic Research Center, Myrtle Beach

32114

RECRUITING

Advanced Urology Institute, Daytona Beach

44130

RECRUITING

Clinical Research Solutions, Cleveland

47130

RECRUITING

First Urology, Jeffersonville

48084

RECRUITING

Michigan Institute of Urology, Troy

78229

RECRUITING

Urology San Antonio, San Antonio

80211

RECRUITING

The Urology Center of Colorado, Denver

99202

RECRUITING

Spokane Urology, Spokane

08054

RECRUITING

New Jersey Urology, Mount Laurel